Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.

News Releases

view all
    • News in Focus
        • Browse News Releases

        • All Public Company News
        • All Multimedia News
        • View All News Releases

        • Regulatory News

        • D/A/CH Regulatory News
        • UK Regulatory News
        • View All Regulatory News

    • Business & Money
        • Auto & Transportation

        • Aerospace & Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads & Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking & Road Transportation
        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film & Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers & Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalisation
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls & Research
        • Trade Show News
        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil & Gas Discoveries
        • Utilities
        • Water Utilities
        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defence
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation & Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking & Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers & Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines & Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics & Personal Care
        • Fashion
        • Food & Beverages
        • Furniture & Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewellery
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film & Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • View All Sports

        • Travel

        • Amusement Parks & Tourist Attractions
        • Gambling & Casinos
        • Hotels & Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Animal Welfare
        • Corporate Social Responsibility
        • Economic News, Trends & Analysis
        • Education
        • Environmental
        • European Government
        • Labour & Union
        • Natural Disasters
        • Not For Profit
        • Public Safety
        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Enquiries
    • Media Enquiries
    • Partnerships
    • Hamburger menu
    • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
    • Send a Release
      • Phone

      • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

      • ALL CONTACT INFO
      • Contact Us

        +44 (0)20 7454 5110
        from 8 AM - 5:30 PM GMT

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      • 2 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      • General Enquiries
      • Media Enquiries
      • Partnerships
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Regulatory News
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      AbbVie Reports Second-Quarter 2015 Financial Results


      News provided by

      AbbVie

      24 Jul, 2015, 11:57 GMT

      Share this article

      Share this article


      - Reports Second-Quarter Adjusted EPS of $1.08, Up 31.7 Percent and Exceeding Previous Guidance Range of $1.04 to $1.06 (Reports GAAP EPS of $0.83)

      - Delivers Second-Quarter Revenue of $5.475 Billion, an Increase of 19.4 Percent Over Second-Quarter 2014 on an Operational Basis (Excluding 8.3 Percent Unfavorable Exchange). Reported Sales Increased 11.1 Percent

      - Revenue Growth Reflects 16.4 Percent Global Operational Sales Growth from HUMIRA (Excluding 8.8 Percent Unfavorable Exchange). Reported Global HUMIRA Sales Increased 7.6 Percent

      - Second Quarter U.S. Sales of IMBRUVICA were $234 Million; AbbVie Recorded Partial Quarter U.S. Sales of $97 Million

      - Second Quarter Global VIEKIRA Sales were $385 Million

      - Delivers Adjusted Operating Margin Expansion to 44.2 Percent of Sales; Gross Margin Improves to 85.3 Percent of Sales

      - Confirms 2015 Adjusted EPS Guidance Range of $4.10 to $4.30 (GAAP EPS Range of $3.26 to $3.46)

      NORTH CHICAGO, Illinois, July 24, 2015 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced financial results for the second quarter ended June 30, 2015.

      "We are pleased with the high level of performance we've delivered through the first-half of 2015, consistent with our commitment to shareholders for top-tier growth this year and beyond," said Richard A. Gonzalez, chairman and chief executive officer, AbbVie. "With the completion of the Pharmacyclics transaction, continued momentum from our on-market products and rapid evolution of our robust development pipeline, we are well positioned to deliver strong performance in the future."

      Second-Quarter Results

      • Worldwide sales were $5.475 billion in the second quarter, up 11.1 percent year-over-year. On an operational basis, sales increased 19.4 percent, excluding an 8.3 percent unfavorable impact from foreign exchange rate fluctuations.
      • Second-quarter sales growth was driven by the continued strength of HUMIRA and other promoted products. Global HUMIRA sales increased 16.4 percent on an operational basis, or 7.6 percent including the impact of foreign exchange rate fluctuations. Strong U.S. HUMIRA growth continued, driven by double-digit growth across all three major market categories, rheumatology, dermatology and gastroenterology. Reported international HUMIRA sales growth in the quarter was reduced by nearly 18 percent due to unfavorable foreign exchange. First-half 2015 international HUMIRA sales grew nearly 9 percent on an operational basis, consistent with planning expectations and the full year forecast for international HUMIRA sales growth of 9 to 10 percent on an operational basis. As noted last quarter, the first-quarter international operational growth rate of nearly 15 percent was favorably impacted by the timing of shipments in select markets. Consequently, sales growth in the second quarter was negatively impacted by shipment timing.
      • Total company sales growth was also driven by $385 million in global VIEKIRA sales, now approved in 47 countries with additional approvals anticipated throughout the remainder of 2015, as well as strong operational growth from other key products including Creon, Synthroid and Duodopa.
      • Second-quarter U.S. IMBRUVICA sales were $234 million. AbbVie recorded a partial quarter of U.S. IMBRUVICA sales of $97 million and $10 million of international profit sharing based on the May 26 close date of the Pharmacyclics acquisition.
      • The adjusted gross margin ratio in the second quarter was 85.3 percent, excluding intangible asset amortization and other specified items. Gross margin expansion was driven by product mix, operating efficiencies and the impact of foreign exchange rates. The gross margin ratio under U.S. generally accepted accounting principles (GAAP) was 83.3 percent.
      • Adjusted selling, general and administrative (SG&A) expense was 25.1 percent of sales in the second quarter. On a GAAP basis, SG&A was 31.1 percent of sales.
      • Adjusted research and development (R&D) was 15.9 percent of sales in the quarter, reflecting funding actions in support of our mid- and late-stage pipeline assets. On a GAAP basis, R&D was 17.9 percent of sales.
      • The adjusted operating margin in the second quarter was 44.2 percent, compared to 36.4 percent in second-quarter 2014. On a GAAP basis, the operating margin was 33.8 percent.
      • Adjusted net interest expense was $137 million, which reflects the impact of debt issued in conjunction with the Pharmacyclics acquisition. The adjusted tax rate was 21.9 percent in the quarter and 18.6 percent on a GAAP basis.
      • Adjusted diluted earnings per share, excluding intangible asset amortization expense and other specified items, were $1.08 in the second quarter, up 31.7 percent. Diluted earnings per share were $0.83 on a GAAP basis.

      Key Events from the Second Quarter

      • On May 26, AbbVie successfully completed the acquisition of Pharmacyclics, accelerating AbbVie's clinical and commercial presence in oncology. The acquisition aligns strategically to AbbVie's business model, strengthening the company's already robust oncology pipeline and further diversifying AbbVie's revenue base.
      • AbbVie announced that the European Commission granted marketing authorization for IMBRUVICA (ibrutinib) as the first treatment option specifically approved for treatment of adult patients with Waldenstrom's macroglobulinemia.
      • Results from the Phase 3 HELIOS study of IMBRUVICA were presented at The American Society of Clinical Oncology (ASCO) meeting. The data demonstrated that patients with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) experienced an 80 percent reduction in the risk of disease progression or death when treated with ibrutinib in combination with bendamustine and rituximab, compared to patients receiving placebo in combination with bendamustine and rituximab.
      • AbbVie reported top-line results from the head-to-head Phase 3, RESONATE-2 study, which evaluated efficacy and safety of ibrutinib versus traditional chemotherapy, chlorambucil. Initial findings showed that treatment with ibrutinib improved progression-free survival rates, as well as met several secondary endpoints, including overall survival and overall response rates when used in treatment-naïve patients with CLL and SLL. Additional detailed data will be presented at an upcoming medical meeting. AbbVie anticipates submitting these data for regulatory review in the second-half of 2015.
      • AbbVie announced its investigational medicine venetoclax, an inhibitor of the B-cell lymphoma-2 (BCL-2) protein that is being developed in partnership with Genentech and Roche, has been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for the treatment of CLL in previously treated (relapsed/refractory) patients with the 17p deletion genetic mutation. The 17p deletion mutation is a genomic alteration in which a part of chromosome 17 is absent. The median life expectancy for CLL patients with 17p deletion is less than 2-3 years. AbbVie expects to submit regulatory applications to U.S. and European agencies for this indication before the end of 2015.
      • Data from the Phase 3 ELOQUENT-2 study of elotuzumab were recently published in the New England Journal of Medicine. Elotuzumab is being developed in partnership with Bristol Myers Squibb, for front-line and relapsed/refractory multiple myeloma. Data showed that adding elotuzumab to standard of care in patients with relapsed/refractory multiple myeloma significantly reduced the risk of disease progression and demonstrated superior progression-free survival and overall response rates. The regulatory submissions are anticipated in the second-half of 2015.
      • The FDA granted priority review to AbbVie for its investigational, all-oral, interferon-free (IFN) therapy for the treatment of genotype 4 (GT4) chronic HCV in the United States. The New Drug Application (NDA) was accepted by the agency and is based on results from the PEARL-I study, which demonstrated 100 percent sustained virologic response rate at 12 weeks post-treatment (SVR12) when used with ribavirin (RBV), with no discontinuations due to adverse events. This investigational therapy also previously received Breakthrough Therapy Designation, and AbbVie anticipates regulatory action in the second-half of 2015.
      • New, pivotal data from the GIFT-I study of AbbVie's all-oral, IFN- and RBV-free, two direct-acting antiviral (DAA) treatment with ombitasvir/paritaprevir/ritonavir in genotype 1b (GT1b) chronic HCV infected Japanese patients with and without cirrhosis were presented at the Annual Meeting of the Japan Society of Hepatology. Patients were both treatment-naïve and treatment-experienced. Primary endpoints were achieved, demonstrating 95 percent SVR12 in a sub-group of treatment-naïve, non-cirrhotic, adult GT1b chronic HCV infected Japanese patients who were eligible for therapy with IFN and had a high viral load. In study results related to the secondary endpoint, GT1b HCV patients with compensated cirrhosis achieved 91 percent SVR12. AbbVie's two-DAA combination is currently under regulatory review in Japan and a decision is expected in the second-half of 2015.
      • AbbVie reported results from the TURQUOISE-III study in treatment-naïve and treatment-experienced patients with GT1b chronic HCV with compensated liver cirrhosis. These data demonstrated 100 percent SVR12 rates when treated with VIEKIRA without RBV. No patients discontinued treatment due to adverse events. Over time, chronic HCV may lead to liver complications, including compensated cirrhosis, in about 10-20 percent of people infected.
      • AbbVie announced that the FDA granted VIEKIRA orphan drug designation for the investigational treatment of HCV infection in pediatric patients, 0 – 16 years of age. Orphan drug designations recognize the need for a treatment of a rare disease or condition. AbbVie will conduct an investigational clinical study to evaluate the efficacy and safety of VIEKIRA with or without RBV in pediatric patients with chronic HCV infection. VIEKIRA is currently not approved for this indication.
      • AbbVie announced that the FDA granted HUMIRA orphan drug designation for the investigational treatment of moderate-to-severe hidradenitis suppurativa (HS), a painful, chronic inflammatory skin disease. AbbVie's supplemental Biologic License Application (sBLA) is currently under review with the agency. The European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recently granted a positive opinion for this indication.
      • AbbVie recently received approval from the EMA for a new HUMIRA formulation, specifically designed to reduce injection pain and reduce injection volume.
      • AbbVie announced results from VISUAL‑I, a Phase 3 study investigating the efficacy and safety of HUMIRA in adult patients with uveitis. Results showed HUMIRA significantly lowered their risk of uncontrolled uveitis or vision loss. In May 2014, AbbVie received orphan drug designation from the FDA for the investigational treatment of certain forms of non‑infectious uveitis with HUMIRA. U.S. and EU regulatory submissions are expected in the second-half of 2015, following positive results from the second pivotal trial.
      • On June 18, the AbbVie board of directors declared a quarterly cash dividend of $0.51 per share, payable Aug. 14, 2015 to stockholders of record at the close of business on July 15, 2015. Since the company's inception in 2013, AbbVie has increased its dividend by 28 percent.

      Full-Year 2015 Outlook

      AbbVie is confirming its adjusted diluted earnings-per-share guidance for the full-year 2015 of $4.10 to $4.30. The company's 2015 adjusted diluted earnings-per-share guidance excludes $0.84 per share of intangible asset amortization expense, deal costs, integration, and other specified items, and includes $0.20 of dilution related to the Pharmacyclics acquisition. AbbVie's diluted earnings-per-share guidance is $3.26 to $3.46 on a GAAP basis.

      About AbbVie

      AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. Together with its wholly-owned subsidiary, Pharmacyclics, AbbVie employs more than 28,000 people worldwide and markets medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, please visit www.abbvie.com. Follow @abbvie on Twitter or view careers on our Facebook or LinkedIn page.

      Conference Call

      AbbVie will host an investor conference call today at 8:00 a.m. Central time to discuss our second-quarter performance. Participating on the call will be Rick Gonzalez, chairman and chief executive officer; Bill Chase, executive vice president and chief financial officer; Laura Schumacher, executive vice president, business development, external affairs and general counsel; Mike Severino, executive vice president, research and development and chief scientific officer; and Larry Peepo, vice president of investor relations. The call will be webcast through AbbVie's Investor Relations Web site at www.abbvieinvestor.com. An archived edition of the call will be available after 11:00 a.m. Central time.

      Non-GAAP Financial Results

      Financial results for 2014 and 2015 are presented on both a reported and a non-GAAP basis. Reported results were prepared in accordance with GAAP and include all revenue and expenses recognized during the period. Non-GAAP results adjust for certain non-cash items and for factors that are unusual or unpredictable, and exclude those costs, expenses, and other specified items presented in the reconciliation tables later in this release. AbbVie's management believes non-GAAP financial measures provide useful information to investors regarding AbbVie's results of operations and assist management, analysts, and investors in evaluating the performance of the business. Non-GAAP financial measures should be considered in addition to, and not as a substitute for, measures of financial performance prepared in accordance with GAAP. The company's 2015 financial guidance is also being provided on both a reported and a non-GAAP basis.

      Forward-Looking Statements

      Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions, among others, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to challenges to intellectual property, and competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," in AbbVie's 2014 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission. AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
















      AbbVie Inc.

      Key Product Revenue

      Quarter Ended June 30, 2015

      (Unaudited)




      % Change vs. 2Q14


      Revenues (in millions)


      International

      Total


      U.S.

      Int'l.

      Total

      U.S.

      Operational

      Reported

      Operational

      Reported

      NET REVENUES

      $3,370

      $2,105

      $5,475

      27.3%

      10.2%

      (7.6%)

      19.4%

      11.1%

      Humira

      2,141

      1,396

      3,537

      28.9

      3.6

      (14.3)

      16.4

      7.6

      Imbruvica

      97

      10a

      107b

      n/m

      n/m

      n/m

      n/m

      n/m

      Viekira

      227

      158

      385

      n/m

      n/m

      n/m

      n/m

      n/m

      Creon

      159

      --

      159

      44.6

      n/a

      n/a

      44.6

      44.6

      Synagis

      -

      46

      46

      n/a

      (25.6)

      (37.2)

      (25.6)

      (37.2)

      Lupron

      156

      42

      198

      17.2

      (8.5)

      (20.4)

      9.9

      6.5

      Synthroid

      187

      --

      187

      11.9

      n/a

      n/a

      11.9

      11.9

      Kaletra

      43

      124

      167

      (22.4)

      (13.5)

      (22.7)

      (15.8)

      (22.6)

      AndroGel

      170

      --

      170

      (22.1)

      n/a

      n/a

      (22.1)

      (22.1)

      Sevoflurane

      20

      98

      118

      (12.6)

      (13.5)

      (25.5)

      (13.3)

      (23.6)

      Duodopa

      3

      52

      55

      n/m

      17.3

      (5.6)

      20.9

      (2.0)


      Note: "Operational" growth reflects the percentage change over the prior year excluding the impact of exchange rate fluctuations.


      n/a = not applicable

      n/m = not meaningful



      a

      Reflects profit sharing for Imbruvica International revenues

      b

      Reflects partial quarter Imbruvica revenue based on the May 26 close date of the Pharmacyclics acquisition; full-quarter U.S. sales were $234 million



      AbbVie Inc.

      Key Product Revenues

      Six Months Ended June 30, 2015

      (Unaudited)




      % Change vs. 6M14


      Revenues (in millions)


      International

      Total


      U.S.

      Int'l.

      Total

      U.S.

      Operational

      Reported

      Operational

      Reported

      NET REVENUES

      $6,020

      $4,495

      $10,515

      23.5%

      13.4%

      (2.6%)

      18.6%

      10.8%

      Humira

      3,805

      2,843

      6,648

      33.4

      8.8

      (7.5)

      20.7

      12.2

      Imbruvica

      97

      10a

      107b

      n/m

      n/m

      n/m

      n/m

      n/m

      Viekira

      365

      251

      616

      n/m

      n/m

      n/m

      n/m

      n/m

      Creon

      286

      --

      286

      31.9

      n/a

      n/a

      31.9

      31.9

      Synagis

      --

      381

      381

      n/a

      2.2

      (11.0)

      2.2

      (11.0)

      Lupron

      306

      84

      390

      12.0

      (7.0)

      (17.5)

      6.9

      4.0

      Synthroid

      373

      --

      373

      15.3

      n/a

      n/a

      15.3

      15.3

      Kaletra

      84

      263

      347

      (23.0)

      (1.1)

      (12.9)

      (6.9)

      (15.6)

      AndroGel

      323

      --

      323

      (31.7)

      n/a

      n/a

      (31.7)

      (31.7)

      Sevoflurane

      38

      206

      244

      (8.2)

      (7.7)

      (19.0)

      (7.8)

      (17.5)

      Duodopa

      3

      105

      108

      n/m

      18.1

      (2.4)

      20.3

      (0.2)


      Note: "Operational" growth reflects the percentage change over the prior year excluding the impact of exchange rate fluctuations.


      n/a = not applicable

      n/m = not meaningful


      a Reflects profit sharing for Imbruvica International revenues

      b Reflects Imbruvica revenue from the May 26 close date of the Pharmacyclics acquisition



      AbbVie Inc.

      Consolidated Statements of Earnings

      Quarter and Six Months Ended June 30, 2015 and 2014

      (Unaudited) (In millions, except per share data)



      Second Quarter
      Ended June 30


      Six Months
      Ended June 30



      2015


      2014


      2015


      2014


      Net revenues

      $5,475


      $4,926


      $10,515


      $9,489











      Cost of products sold

      916


      1,113


      1,858


      2,213


      Selling, general and administrative

      1,703


      1,448


      3,176


      2,788


      Research and development

      981


      834


      1,792


      1,606


      Acquired in-process research and development

      23


      16


      150


      16


      Total operating cost and expenses

      3,623


      3,411


      6,976


      6,623











      Operating earnings

      1,852


      1,515


      3,539


      2,866











      Interest expense, net

      164


      69


      290


      134


      Net foreign exchange loss

      14


      5


      178


      8


      Other (income) expense, net

      (4)


      8


      (3)


      5


      Earnings before income tax expense

      1,678


      1,433


      3,074


      2,719


      Income tax expense

      312


      335


      686


      641


      Net earnings

      $1,366


      $1,098


      $2,388


      $2,078











      Diluted earnings per share

      $0.83


      $0.68


      $1.47


      $1.29











      Diluted earnings per share, excluding specified items

      $1.08


      $0.82


      $2.03


      $1.53

      a)










      Average diluted shares outstanding

      1,633


      1,608


      1,621


      1,608













      a) Refer to the Reconciliation of GAAP Reported to Non-GAAP Adjusted Information for further details.




      AbbVie Inc.

      Reconciliation of GAAP Reported to Non-GAAP Adjusted Information

      Quarter Ended June 30, 2015

      (Unaudited) (In millions, except per share data)


      1. Specified items impacted results as follows:



      2Q15


      Earnings

      Diluted


      Pre-tax

      After-tax

      EPS

      As reported (GAAP)

      $1,678

      $1,366

      $0.83

      Adjusted for specified items:




      Intangible asset amortization

      86

      66

      0.04

      Separation costs

      95

      80

      0.05

      Acquired IPR&D

      23

      23

      0.01

      Pharmacyclics transaction and other costs

      359

      215

      0.13

      Other

      34

      26

      0.02

      As adjusted (non-GAAP)

      $2,275

      $1,776

      $1.08



      Intangible asset amortization reflects costs recognized as a result of licensing and acquisition activities. Separation costs are expenses related to the separation of AbbVie from Abbott. Acquired IPR&D primarily reflects an upfront payment related to a licensing arrangement with a third party. Pharmacyclics transaction and other costs reflect transaction, financing, integration and other costs related to the acquisition of Pharmacyclics. Other is primarily associated with restructuring activities.





      2.

      The impact of the specified items by line item was as follows:




      2Q15


      Cost of products
      sold

      SG&A

      R&D

      Acquired

      IPR&D

      Interest expense

      As reported (GAAP)

      $916

      $1,703

      $981

      $23

      $164

      Adjusted for specified items:






      Intangible asset amortization

      (86)

      --

      --

      --

      --

      Separation costs

      (2)

      (93)

      --

      --

      --

      Acquired IPR&D

      --

      --

      --

      (23)

      --

      Pharmacyclics transaction and other costs

      (19)

      (220)

      (93)

      --

      (27)

      Other

      (3)

      (15)

      (16)

      --

      --

      As adjusted (non-GAAP)

      $806

      $1,375

      $872

      --

      $137



      3. The adjusted tax rate for the second quarter of 2015 was 21.9 percent, as detailed below:




      2Q15


      Pre-tax

      Income



      income

      taxes

      Tax rate

      As reported (GAAP)

      $1,678

      $312

      18.6%

      Specified items

      597

      187

      31.3%

      As adjusted (non-GAAP)

      $2,275

      $499

      21.9%



      AbbVie Inc.

      Reconciliation of GAAP Reported to Non-GAAP Adjusted Information

      Quarter Ended June 30, 2014

      (Unaudited) (In millions, except per share data)


      1. Specified items impacted results as follows:



      2Q14


      Earnings

      Diluted


      Pre-tax

      After-tax

      EPS

      As reported (GAAP)

      $1,433

      $1,098

      $0.68

      Adjusted for specified items:




      Intangible asset amortization

      99

      69

      0.04

      Separation costs

      110

      96

      0.06

      R&D

      40

      40

      0.02

      Acquired IPR&D

      16

      16

      0.01

      Restructuring/Other

      12

      11

      0.01

      As adjusted (non-GAAP)

      $1,710

      $1,330

      $0.82









      Intangible asset amortization reflects costs recognized as a result of licensing and acquisition activities. Separation costs are expenses related to the separation of AbbVie from Abbott. R&D is associated with a milestone payment for a previously-announced collaboration. Acquired IPR&D reflects an upfront payment related to a licensing arrangement with a third party. Restructuring/Other is associated with previously announced restructuring activities.



      2.

      The impact of the specified items by line item was as follows:




      2Q14


      Cost of
      products
      sold

      SG&A

      R&D

      Acquired
      IPR&D

      As reported (GAAP)

      $1,113

      $1,448

      $834

      $16

      Adjusted for specified items:





      Intangible asset amortization

      (99)

      --

      --

      --

      Separation costs

      (3)

      (106)

      (1)

      --

      R&D

      --

      --

      (40)

      --

      Acquired IPR&D

      --

      --

      --

      (16)

      Restructuring/Other

      (6)

      (6)

      --

      --

      As adjusted (non-GAAP)

      $1,005

      $1,336

      $793

      --



      3.

      The adjusted tax rate for the second quarter of 2014 was 22.2 percent, as detailed below:




      2Q14


      Pre-tax

      Income



      income

      taxes

      Tax rate

      As reported (GAAP)

      $1,433

      $335

      23.4%

      Specified items

      277

      45

      16.2%

      As adjusted (non-GAAP)

      $1,710

      $380

      22.2%



      AbbVie Inc.

      Reconciliation of GAAP Reported to Non-GAAP Adjusted Information

      Six Months Ended June 30, 2015

      (Unaudited) (In millions, except per share data)


      1. Specified items impacted results as follows:



      6M15


      Earnings

      Diluted


      Pre-tax

      After-tax

      EPS

      As reported (GAAP)

      $3,074

      $2,388

      $1.47

      Adjusted for specified items:




      Intangible asset amortization

      154

      118

      0.07

      Separation costs

      199

      169

      0.10

      Acquired IPR&D

      150

      150

      0.09

      Pharmacyclics transaction and other costs

      420

      256

      0.16

      Shire termination

      170

      170

      0.10

      Other

      68

      49

      0.04

      As adjusted (non-GAAP)

      $4,235

      $3,300

      $2.03









      Intangible asset amortization reflects costs recognized as a result of licensing and acquisition activities. Separation costs are expenses related to the separation of AbbVie from Abbott. Acquired IPR&D primarily reflects the C2N collaboration. Pharmacyclics transaction and other costs reflect transaction, financing, integration and other costs related to the acquisition of Pharmacyclics. Shire termination reflects the completed liquidation of remaining foreign currency positions related to the terminated Shire transaction, as communicated in the fourth quarter of 2014. Other is primarily associated with restructuring activities.



      2.

      The impact of the specified items by line item was as follows:






      6M15


      Cost of products sold

      SG&A

      R&D

      Acquired IPR&D

      Interest

      expense

      Foreign exchange (gain)/loss

      As reported (GAAP)

      $1,858

      $3,176

      $1,792

      $150

      $290

      $178

      Adjusted for specified items:







      Intangible asset amortization

      (154)

      --

      --

      --

      --

      --

      Separation costs

      (5)

      (194)

      --

      --

      --

      --

      Acquired IPR&D

      --

      --

      --

      (150)

      --

      --

      Pharmacyclics transaction and other costs

      (19)

      (222)

      (93)

      --

      (86)

      --

      Shire termination

      --

      --

      --

      --

      --

      (170)

      Other

      (12)

      (40)

      (16)

      --

      --

      --

      As adjusted (non-GAAP)

      $1,668

      $2,720

      $1,683

      --

      $204

      $8



      3.

      The adjusted tax rate for the first half of 2015 was 22.1 percent, as detailed below:




      6M15


      Pre-tax

      Income



      income

      taxes

      Tax rate

      As reported (GAAP)

      $3,074

      $686

      22.3%

      Specified items

      1,161

      249

      21.4%

      As adjusted (non-GAAP)

      $4,235

      $935

      22.1%



      AbbVie Inc.

      Reconciliation of GAAP Reported to Non-GAAP Adjusted Information

      Six Months Ended June 30, 2014

      (Unaudited) (In millions, except per share data)


      1. Specified items impacted results as follows:



      6M14


      Earnings

      Diluted


      Pre-tax

      After-tax

      EPS

      As reported (GAAP)

      $2,719

      $2,078

      $1.29

      Adjusted for specified items:




      Intangible asset amortization

      209

      148

      0.09

      Separation costs

      190

      184

      0.11

      R&D

      40

      40

      0.02

      Acquired IPR&D

      16

      16

      0.01

      Restructuring/Other

      16

      14

      0.01

      As adjusted (non-GAAP)

      $3,190

      $2,480

      $1.53








      Intangible asset amortization reflects costs recognized as a result of licensing and acquisition activities. Separation costs are expenses related to the separation
      of AbbVie from Abbott. R&D is associated with a milestone payment for a previously-announced collaboration. Acquired IPR&D reflects an upfront payment
      related to a licensing arrangement with a third party. Restructuring/Other is associated with previously announced restructuring activities.



      2.

      The impact of the specified items by line item was as follows:




      6M14


      Cost of
      products
      sold

      SG&A

      R&D

      Acquired
      IPR&D

      As reported (GAAP)

      $2,213

      $2,788

      $1,606

      $16

      Adjusted for specified items:





      Intangible asset amortization

      (209)

      --

      --

      --

      Separation costs

      (6)

      (182)

      (2)

      --

      R&D

      --

      --

      (40)

      --

      Acquired IPR&D

      --

      --

      --

      (16)

      Restructuring/Other

      (7)

      (9)

      --

      --

      As adjusted (non-GAAP)

      $1,991

      $2,597

      $1,564

      --



      3.

      The adjusted tax rate for the first half of 2014 was 22.3 percent, as detailed below:




      6M14


      Pre-tax

      Income



      income

      taxes

      Tax rate

      As reported (GAAP)

      $2,719

      $641

      23.6%

      Specified items

      471

      69

      14.6%

      As adjusted (non-GAAP)

      $3,190

      $710

      22.3%

      Modal title

      Also from this source

      AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

      AbbVie (NYSE: ABBV) today announced that the European Commission (EC) granted marketing authorization for TEPKINLY® (epcoritamab) in combination with ...

      AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

      AbbVie (NYSE: ABBV) today announced topline results from the Phase 3 EPCORE DLBCL-4 trial evaluating the combination of epcoritamab, a T-cell...

      More Releases From This Source

      Explore

      Health Care & Hospitals

      Health Care & Hospitals

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Pharmaceuticals

      Pharmaceuticals

      Banking & Financial Services

      Banking & Financial Services

      News Releases in Similar Topics

      Contact PR Newswire

      • +44 (0)20 7454 5110
        from 8 AM - 5:30 PM GMT
      • General Enquiries
      • Media Enquiries
      • Partnerships

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United States
      • Vietnam

      My Services

      • All News Releases
      • PR Newswire Amplify™
      • Resources
      • Journalists
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via Privacy@cision.com 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Customer Portal
      • Resources
      • Journalists
      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookie Settings
      Copyright © 2026 PR Newswire Europe Limited. All Rights Reserved. A Cision company.